Accendra Health Inc
Statements
Segments
US companies must disclose in their mandatory reports how revenue breaks down across business segments, regions and product lines. We read that breakdown for you straight from the annual and quarterly reports (10-K and 10-Q) of Accendra Health Inc (ACH). It shows which part of the business is growing — and which one is holding it back.
Revenue by business segment
| Segment | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Products & Healthcare Services | $7.66B 90.4% | $8.83B 90.2% · +15.2% | $7.90B 79.3% · -10.5% | $7.78B 75.3% · -1.5% | $8.02B 75.0% · +3.1% |
| Patient Direct | $817.7M 9.6% | $959.7M 9.8% · +17.4% | $2.06B 20.7% · +114.4% | $2.55B 24.7% · +24.1% | $2.68B 25.0% · +5.0% |
Large figure: segment revenue. Below it the share of revenue in that period and the change against the prior year.
| Segment | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Products & Healthcare Services | $215.7M 2.8% | $384.4M 4.4% | $175.3M 2.2% | $57.8M 0.7% | $53.0M 0.7% |
| Patient Direct | $67.7M 8.3% | $58.0M 6.0% | $193.7M 9.4% | $246.9M 9.7% | $260.2M 9.7% |
Large figure: segment operating income. Below it the margin, that is operating income measured against the revenue of the same segment.
Revenue by region
| Segment | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| United States | $8.13B 95.9% | $9.25B 94.5% · +13.8% | $9.53B 95.7% · +3.0% | $10.06B 97.3% · +5.6% | $10.46B 97.7% · +4.0% |
| International | $349.8M 4.1% | $535.0M 5.5% · +53.0% | $429.4M 4.3% · -19.7% | $275.3M 2.7% · -35.9% | $242.9M 2.3% · -11.8% |
Large figure: segment revenue. Below it the share of revenue in that period and the change against the prior year.
Revenue by product line
| Segment | 2023 | 2024 | 2025 |
|---|---|---|---|
| Diabetes | LOQ723.3M 28.3% | LOQ777.5M 29.0% · +7.5% | LOQ783.4M 28.4% · +0.8% |
| Sleep therapy | LOQ669.8M 26.2% | LOQ703.0M 26.2% · +5.0% | LOQ740.1M 26.8% · +5.3% |
| Home respiratory therapy | LOQ457.7M 17.9% | LOQ436.0M 16.3% · -4.7% | LOQ433.1M 15.7% · -0.7% |
| Other | LOQ255.0M 10.0% | LOQ268.3M 10.0% · +5.2% | LOQ288.2M 10.4% · +7.4% |
| Ostomy | LOQ177.9M 7.0% | LOQ195.9M 7.3% · +10.1% | LOQ212.8M 7.7% · +8.6% |
| Wound care | LOQ170.9M 6.7% | LOQ192.4M 7.2% · +12.6% | LOQ188.5M 6.8% · -2.0% |
| Urology | LOQ98.0M 3.8% | LOQ107.1M 4.0% · +9.3% | LOQ116.0M 4.2% · +8.3% |
Large figure: segment revenue. Below it the share of revenue in that period and the change against the prior year.
Segment and region names are the ones the company itself uses and are shown as reported. Change and share refer to revenue.
Data as of: August 28, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q) · Segment figures: SEC EDGAR (10-K/10-Q reports)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.